Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

The Role Of PET Imaging For Predicting Treatment Failure In Primary Mediastinal B-Cell Lymphoma

Sarah J. Nagle, MD, Elise A. Chong, MD, Seble Chekol, MD, Nirav N. Shah, MD, Sunita D. Nasta, MD, Eli Glatstein, MD, John P. Plastaras, MD PhD, Drew Torigian, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD

Blood (2013) 122 (21): 4302.

https://doi.org/10.1182/blood.V122.21.4302.4302

Published: 2013

Journal Articles

Radiation Therapy In Peripheral T-Cell Lymphoma Of The Head and Neck

Annemarie T. Fernandes, MD, Jakub Svoboda, MD, Sunita D. Nasta, MD, Lynn D. Wilson, MD, John P. Plastaras, MD PhD

Blood (2013) 122 (21): 1795.

https://doi.org/10.1182/blood.V122.21.1795.1795

Published: 2013

Journal Articles

Risk Factors For Radiation Pneumonitis In Patients With Lymphoma Treated With Chemotherapy and Photon Or Proton Radiotherapy

Anna Mesina, BS, Surbhi Grover, MD MPH, Carmen Mesina, BS MS, Sunita D. Nasta, MD, Jakub Svoboda, MD, John P. Plastaras, MD PhD

Blood (2013) 122 (21): 5101.

https://doi.org/10.1182/blood.V122.21.5101.5101

Published: 2013

Journal Articles

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

Elise A. Chong, MD, Tahamtan Ahmadi, MD, PhD, Nicole A. Aqui, MD, Sunita D. Nasta, MD, Jakub Svoboda, MD, Kristy M. Walsh, BS, Amanda Gordon, CRNP, Stephen J. Schuster, MD

Blood (2013) 122 (21): 250.

https://doi.org/10.1182/blood.V122.21.250.250

Published: 2013

Journal Articles

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

Daniel J. Landsburg, MD, Edward A. Stadtmauer, MD, Alison W. Loren, MD, Steven C. Goldstein, MD, Noelle V. Frey, MD, Sunita D. Nasta, MD, David L Porter, MD, Donald E Tsai, MD PhD, Alexander E Perl, MD, Elizabeth Hexner, MD, Selina Luger, MD

Blood (2012) 120 (21): 2600.

https://doi.org/10.1182/blood.V120.21.2600.2600

Published: 2012

Journal Articles

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Sarah J. Nagle, MD, Kaitlin Woo, Rosemarie Mick, MS, Stephen J. Schuster, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jakub Svoboda, MD

Blood (2012) 120 (21): 2689.

https://doi.org/10.1182/blood.V120.21.2689.2689

Published: 2012

Journal Articles

Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up

Stephen J. Schuster, MD, Nicole A. Aqui, MD, Benjamin Musher, MD, Bruce L. Levine, PhD, Charalambos Andreadis, MD, MS, Elise A. Chong, BA, Sunita D. Nasta, MD, Amanda Gordon, CRNP, Julio Cotte, Zhaohui Zheng, MA, Andrea L. Brennan, Elizabeth Veloso, JD, BSN, Carl H. June, MD

Blood (2012) 120 (21): 1631.

https://doi.org/10.1182/blood.V120.21.1631.1631

Published: 2012

Journal Articles

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Marc Hoffmann, MD, Tahamtan Ahmadi, MD, PhD, Erin Cobain, MD, Alison Loren, Noelle V Frey, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 4950.

https://doi.org/10.1182/blood.V118.21.4950.4950

Published: 2011

Journal Articles

Maximum Standard Uptake Value (SUVmax) on FDG-PET Imaging Predicts Time to First Treatment in Patients with Low Grade Follicular Lymphoma,

Jakub Svoboda, MD, Elise A. Chong, BA, Emeline R Chong, Sunita D. Nasta, MD, Drew Torigian, MD, Abass Alavi, MD, Stephen J. Schuster, MD

Blood (2011) 118 (21): 4204.

https://doi.org/10.1182/blood.V118.21.4204.4204

Published: 2011

Journal Articles

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Erin Cobain, MD, Tahamtan Ahmadi, MD, PhD, Marc Hoffmann, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Jakub Svoboda, MD, Selina Luger, MD, Edward A. Stadtmauer, MD, Sunita D. Nasta, MD

Blood (2011) 118 (21): 2689.

https://doi.org/10.1182/blood.V118.21.2689.2689

Published: 2011

Journal Articles

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, CRNP, Nicole A. Aqui, MD, YinYan Xu, Jakub Svoboda, MD, Sunita D. Nasta, MD, Stephen J. Schuster, MD

Blood (2011) 118 (21): 266.

https://doi.org/10.1182/blood.V118.21.266.266

Published: 2011

Journal Articles

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Ran Reshef, MD, Selina M. Luger, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, James A. Hoxie, MD, Stephen G. Emerson, MD, PhD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2011) 118 (21): 1011.

https://doi.org/10.1182/blood.V118.21.1011.1011

Published: 2011

Journal Articles

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

Tahamtan Ahmadi, MD, PhD, Elise A. Chong, BA, Amanda Gordon, BA, BSN, RN, Nicole A. Aqui, MD, Lisa H. Downs, CRNP, Leah Leinbach, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Stephen Janofsky, Tapan N. Maniar, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD

Blood (2009) 114 (22): 1700.

https://doi.org/10.1182/blood.V114.22.1700.1700

Published: 2009

Journal Articles

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

Andres Forero-Torres, MD, Nancy L Bartlett, MD, Sunita D Nasta, MD, Donald Northfelt, MD, Anne Beaven, MD, Han Myint, FRCP, FRCPath, Nancy C Whiting, PharmD, BCOP, Jonathan G Drachman, MD, Craig H Moskowitz, MD

Blood (2009) 114 (22): 586.

https://doi.org/10.1182/blood.V114.22.586.586

Published: 2009

Journal Articles

The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma

Shahrzad Abdollahi, Elise A Chong, BA, Rebecca L. Olin, MD, Sunita D. Nasta, MD, Charalambos Andreadis, MD, MSCE, Edward A Stadtmauer, MD, Christopher C Lake, Lisa H Downs, Stephen J. Schuster, MD

Blood (2008) 112 (11): 3783.

https://doi.org/10.1182/blood.V112.11.3783.3783

Published: 2008

Journal Articles

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Dan T. Vogl, MD, Selina Luger, MD, David L. Porter, MD, Elise A. Chong, Stephen J. Schuster, MD, Donald E. Tsai, MD, Alexander Perl, MD, Alison W. Loren, MD, MS, Stephen Goldstein, MD, Sunita D. Nasta, MD, Charalambos Andreadis, MD, Patricia A. Mangan, Kimberly Hummel, Donald L. Siegel, MD, PhD, Eli Glatstein, MD, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1171.

https://doi.org/10.1182/blood.V106.11.1171.1171

Published: 2005

NARROW

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

The Role Of PET Imaging For Predicting Treatment Failure In Primary Mediastinal B-Cell Lymphoma

Radiation Therapy In Peripheral T-Cell Lymphoma Of The Head and Neck

Risk Factors For Radiation Pneumonitis In Patients With Lymphoma Treated With Chemotherapy and Photon Or Proton Radiotherapy

High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up

A Study of Outcomes of Diffuse Large B Cell Lymphoma in the Elderly

Maximum Standard Uptake Value (SUVmax) on FDG-PET Imaging Predicts Time to First Treatment in Patients with Low Grade Follicular Lymphoma,

B Cell Lymphoma, Unclassifiable: Survival Advantage for Aggressive Therapy

Phase II Trial of Lenalidomide - Rituximab +/− Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.

A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.

The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma

Thalidomide and Dexamethasone Induction Therapy Is Associated with Superior Progression-Free Survival after Autotransplant for Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only